AU2002229994A1 - Albumin-based drug delivery system and antimicrobial peptides - Google Patents

Albumin-based drug delivery system and antimicrobial peptides

Info

Publication number
AU2002229994A1
AU2002229994A1 AU2002229994A AU2002229994A AU2002229994A1 AU 2002229994 A1 AU2002229994 A1 AU 2002229994A1 AU 2002229994 A AU2002229994 A AU 2002229994A AU 2002229994 A AU2002229994 A AU 2002229994A AU 2002229994 A1 AU2002229994 A1 AU 2002229994A1
Authority
AU
Australia
Prior art keywords
albumin
delivery system
drug delivery
antimicrobial peptides
based drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002229994A
Other languages
English (en)
Inventor
Rohanah Hussain
Giuliano Siligardi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London filed Critical Kings College London
Publication of AU2002229994A1 publication Critical patent/AU2002229994A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2002229994A 2001-02-16 2002-02-15 Albumin-based drug delivery system and antimicrobial peptides Abandoned AU2002229994A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0103877.7A GB0103877D0 (en) 2001-02-16 2001-02-16 Novel Drug Delivery system
GB0103877.7 2001-02-16
PCT/GB2002/000680 WO2002066067A2 (en) 2001-02-16 2002-02-15 Albumin-based drug delivery system and antimicrobial peptides

Publications (1)

Publication Number Publication Date
AU2002229994A1 true AU2002229994A1 (en) 2002-09-04

Family

ID=9908913

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002229994A Abandoned AU2002229994A1 (en) 2001-02-16 2002-02-15 Albumin-based drug delivery system and antimicrobial peptides

Country Status (7)

Country Link
US (1) US20040110678A1 (enExample)
EP (1) EP1359941A2 (enExample)
JP (1) JP2004521911A (enExample)
AU (1) AU2002229994A1 (enExample)
CA (1) CA2476397A1 (enExample)
GB (1) GB0103877D0 (enExample)
WO (1) WO2002066067A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
WO2005013885A2 (en) 2003-08-07 2005-02-17 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
WO2007026356A2 (en) * 2005-08-29 2007-03-08 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
WO2008128251A1 (en) * 2007-04-17 2008-10-23 The Children's Hospital Of Philadelphia Humanized viral vectors and methods of use thereof
EP2653166A3 (en) * 2007-07-30 2014-08-27 Healor Ltd. Pharmaceutical composition and related methods
ES2601827T3 (es) * 2009-02-24 2017-02-16 Arava Bio-Tech Ltd. Agentes antagonistas de visfatina para el tratamiento del acné y de otras afecciones
WO2011083483A2 (en) 2010-01-11 2011-07-14 Healor Ltd. Method for treatment of inflammatory disease and disorder
AT509192B1 (de) * 2010-06-24 2011-07-15 Zentrum Fuer Biomedizinische Technologie Der Donau Uni Krems Sorptionsmittel für endotoxine
ES2800983T3 (es) * 2010-12-22 2021-01-07 Baxalta GmbH Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína
FR3002452B1 (fr) * 2013-02-28 2016-02-12 Dermaconcept Jmc Composition dermatologique antimicrobienne topique
WO2015136311A1 (en) * 2014-03-13 2015-09-17 The Secretary Of State For Health Antimicrobial conjugates, method for production and uses thereof
US10071141B2 (en) * 2015-05-08 2018-09-11 Spectral Platforms, Inc. Albumin-based non-covalent complexes and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992001476A1 (en) * 1990-07-26 1992-02-06 University Of Iowa Research Foundation Novel drug delivery systems for proteins and peptides using albumin as a carrier molecule
CA2267179A1 (en) * 1996-09-26 1998-04-02 The University Of Southern California Methods and compositions for lipidization of hydrophilic molecules
WO2000033884A1 (en) * 1998-12-04 2000-06-15 Oregon Health Sciences University Conjugates of lipids and antimicrobial or antineoplastic drugs
CA2375502A1 (en) * 1999-06-23 2000-12-28 The Wistar Institute Of Anatomy & Biology Novel pyrrhocoricin-derived peptides, and methods of use thereof
DE10012120A1 (de) * 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel

Also Published As

Publication number Publication date
CA2476397A1 (en) 2002-08-29
JP2004521911A (ja) 2004-07-22
EP1359941A2 (en) 2003-11-12
GB0103877D0 (en) 2001-04-04
WO2002066067A3 (en) 2003-02-13
WO2002066067A2 (en) 2002-08-29
US20040110678A1 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
HUP0401438A3 (en) Drug delivery system
AU2463701A (en) Drug delivery system exhibiting permeability control
AU2002244142A1 (en) Integrated medication delivery system
AU2002341959A1 (en) Drug delivery devices and methods
EP1545662B8 (en) Drug delivery system
AU2002343555A1 (en) Eutectic-based self-nanoemulsified drug delivery system
AU2002326494A1 (en) Products and drug delivery vehicles
AU2003217531A1 (en) Ocular drug delivery systems and use thereof
AU2001244713A1 (en) Transporters and drug delivery system by using the same
IL159875A0 (en) Zero order controlled drug delivery system
AU2002353444A1 (en) Integrated transdermal drug delivery system
AU3520900A (en) Implantable drug delivery system
AUPR573001A0 (en) Lymphatic drug delivery system
AU2002229994A1 (en) Albumin-based drug delivery system and antimicrobial peptides
AU2002219330A1 (en) Activatable cytolytic or drug delivery peptides and uses thereof
AU2002332836A1 (en) Stabilizing catheter for protein drug delivery
AU2003285550A1 (en) Drug delivery system
AU2002222138A1 (en) Drug delivery system
AU2002210580A1 (en) Drug delivery system
HK1065475A (en) Drug delivery system
AU2002319938A1 (en) Drug delivery systems and treatments using them
GB0102725D0 (en) Medical delivery system
AU2002246571A1 (en) Drug delivery systems
AU2002228323A1 (en) Spaced drug delivery system
GB0115136D0 (en) Drug delivery system

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase